San Antonio scientists aim to develop effective method for stem cell delivery to the brain

NewsGuard 100/100 Score

A national science publication has featured the work of San Antonio scientists aiming to develop a more effective method for delivering neural stem cells to the brain in an effort to move forward stem cell therapies to treat neurological disorders.

Dr. Marcel Daadi, Associate Scientist and Director of the Regenerative Medicine and Aging Unit at Texas Biomedical Research Institute's Southwest National Primate Research Center (SNPRC), along with his colleagues at the Research Imaging Institute at the University of Texas Health Science Center at San Antonio (UTHSCSA) and MRI-Interventions Inc. in Irvine, CA published a paper this month in the journal STEM CELLS Translational Medicine titled, "MRI Guided Delivery of Neural Stem Cells into the Basal Ganglia of Nonhuman Primates Reveals a Pulsatile Mode of Cell Dispersion."

Daadi and his colleagues are developing this technology in an effort to treat patients suffering from neurological disorders, like Parkinson's disease, stroke and traumatic brain injury. His research has already developed stem cells capable of becoming dopaminergic cells, which are the cells Parkinson's patients lose over time. An MRI-guided technique to implant these cells would move scientists one step closer to delivery of this therapy to patients.

In the paper, Daadi explains, "Stem cell-based therapy is emerging as a promising treatment for a variety of diseases and injuries. The first step in evaluating the potential of different therapeutic stem cell lines is to develop a safe and effectively reproducible delivery system."

He writes that injection parameters have been well studied in drug delivery methods; however, they simply cannot be directly applied to stem cell-based therapy and the technology for stem cell delivery is undeveloped and limited. Current limitations include inconsistent cell survival, injection site inaccuracy and the inability to avoid puncturing structures like blood vessels, which causes hemorrhages during brain penetration.

He and his colleagues, including Dr. Geoffrey Clarke and Dr. Peter Fox of the Research Imaging Institute at UTHSCSA and the MRI Interventions Inc. team, developed an operational technique for delivering stem cells with low invasiveness and high accuracy in placement of the stem cells to the basal ganglia part of the brain. The basal ganglia controls motor skills compromised in Parkinson's disease.

The team tested the technique on baboons at the SNPRC and not only showed effective targeted delivery but also revealed a pulsatile dispersion of injected cells, meaning cells were not released at a steady rate but instead dispersed in small bursts. This is a significant finding as it demonstrated how injected cells disperse in the host brain and stimulates new ideas on how we can prepare the cells to function at their best.

"We wouldn't have been able to see this phenomenon using standard stereotaxic delivery," said Dr. Daadi. "With iMRI, we can visualize in real time the cells being injected to the target area. A non-invasive iMRI approach is becoming a necessity in clinical applications to enhance the safety of patients and the efficacy of the therapeutic approach. We can create the best cells, but if we can't transplant them to the patient in a consistent and predictable way so that the patient can accept and thrive from them, then the therapy is simply ineffective."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Discovery of new vascular cell type may pave way for novel strategies to treat cardiovascular diseases